HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 07-29-2003, 04:35 AM   #1
Paul
Guest
 
Posts: n/a
Italian researchers have reported that combining thymidine labeling with HER-2 analysis can assist in assigning risk of relapse to patients with node-negative breast cancer receiving loco-regional treatment only. This report appeared in the July 15 2003 issue of the Journal of Clinical Oncology.

  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 10:36 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2017, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter